Two recent positron emission tomography (PET) studies provide critical support that deposition of tau protein tracks and predicts cognitive decline during healthy aging (Marks et al., 2017) and in AD patients (Brier et al., 2016) better than Aβ. This evidence concerns the gene MAPT and Alzheimer disease.